Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.56 | -0.63 | 0.00 |
| FCF Yield | -7.89% | -3.81% | -2.66% |
| EV / EBITDA | -5.58 | -24.63 | -32.01 |
| Quality | |||
| ROIC | -14.93% | -18.20% | 219.02% |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.10 | 0.88 | 0.85 |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -61.90% | -43.22% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 5.94 | 5.76 | 0.11 |
| Interest Coverage | 0.00 | 0.00 | -336.21 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |